ATNX DEADLINE MONDAY: HAGENS BERMAN, National Trial Attorneys, Alerts Athenex (ATNX) Investors to May 3rd Application Deadline in Securities Class Action, Advises Investors with Losses to Contact the Firm Immediately
1, 2021, the market learned the truth when Athenex announced it received the FDA\xe2\x80\x99s complete response letter (\xe2\x80\x9cCRL\xe2\x80\x9d) to the NDA for oral paclitaxel plus encequidar.
- 1, 2021, the market learned the truth when Athenex announced it received the FDA\xe2\x80\x99s complete response letter (\xe2\x80\x9cCRL\xe2\x80\x9d) to the NDA for oral paclitaxel plus encequidar.
- In the CRL, the FDA cited safety risks to patients in terms of an increase in neutropenia-related sequalae.
- Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.
- The firm represents investors, whistleblowers, workers and consumers in complex litigation.\xc2\xa0\xc2\xa0 More about the firm and its successes is located at hbsslaw.com .